Bridge City Capital LLC Sells 22,840 Shares of Harmony Biosciences Holdings, Inc. $HRMY

Bridge City Capital LLC lessened its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 8.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 237,103 shares of the company’s stock after selling 22,840 shares during the quarter. Harmony Biosciences makes up about 2.6% of Bridge City Capital LLC’s portfolio, making the stock its 2nd biggest holding. Bridge City Capital LLC owned approximately 0.41% of Harmony Biosciences worth $8,872,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its stake in Harmony Biosciences by 589.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 752 shares of the company’s stock worth $28,000 after purchasing an additional 643 shares during the last quarter. Leonteq Securities AG acquired a new stake in Harmony Biosciences during the 4th quarter worth $30,000. Allworth Financial LP boosted its stake in Harmony Biosciences by 286.7% during the 4th quarter. Allworth Financial LP now owns 812 shares of the company’s stock worth $30,000 after purchasing an additional 602 shares during the last quarter. Clearstead Advisors LLC boosted its stake in Harmony Biosciences by 145.9% during the 4th quarter. Clearstead Advisors LLC now owns 1,178 shares of the company’s stock worth $44,000 after purchasing an additional 699 shares during the last quarter. Finally, Kestra Advisory Services LLC acquired a new stake in Harmony Biosciences during the 4th quarter worth $47,000. Institutional investors and hedge funds own 86.23% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft cut shares of Harmony Biosciences from a “buy” rating to a “hold” rating and set a $31.00 target price on the stock. in a research note on Monday, February 23rd. Weiss Ratings cut shares of Harmony Biosciences from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. UBS Group reduced their price target on Harmony Biosciences from $46.00 to $36.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Bank of America reduced their price target on Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating on the stock in a report on Wednesday, February 25th. Finally, Wall Street Zen lowered Harmony Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Four research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Harmony Biosciences currently has an average rating of “Hold” and a consensus price target of $40.89.

Harmony Biosciences Stock Down 2.1%

NASDAQ HRMY opened at $34.46 on Friday. Harmony Biosciences Holdings, Inc. has a 52 week low of $25.52 and a 52 week high of $40.87. The company has a quick ratio of 3.56, a current ratio of 3.58 and a debt-to-equity ratio of 0.15. The business’s fifty day simple moving average is $30.86 and its 200-day simple moving average is $33.14. The firm has a market cap of $1.99 billion, a PE ratio of 13.90, a P/E/G ratio of 0.24 and a beta of 0.96.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.21). Harmony Biosciences had a return on equity of 17.19% and a net margin of 16.20%.The company had revenue of $215.39 million for the quarter, compared to analysts’ expectations of $220.84 million. During the same quarter in the prior year, the firm earned $0.78 EPS. The firm’s revenue was up 16.6% on a year-over-year basis. As a group, equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.2 earnings per share for the current year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.